

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
JOCKERS, et al.


Application No.: 10/774,721

Filed: **February 9, 2004**

Title: **OLIGONUCLEOTIDES WHICH INHIBIT
EXPRESSION OF THE OB-RGRP
PROTEIN AND METHOD FOR
DETECTING COMPOUNDS WHICH
MODIFY THE INTERACTION BETWEEN
PROTEINS OF THE OB-RGRP
FAMILY AND THE LEPTIN RECEPTOR**

Examiner: Not Yet Known

Art Unit: Not Yet Known



I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

August 26, 2004

Date of Deposit

Signature

James P. Kelle, Sr.

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98


Mail Stop Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

- ☒ (a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. **18-1982**.

- ☐ (b) This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first.
- ☐ (1) The undersigned attorney certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement;
- ☐ (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or
- ☐ (3) This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Respectfully submitted,



F. Aaron Dubberley, Reg. No., 41,001
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3737
Telefax (908) 231-2626
Aventis Docket No. FRAV2003/0005 US NP

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/774,721	
			Filing Date	02-09-2004	
			First Named Inventor	JOCKERS, et al.	
			Group Art Unit	Not Yet Known	
			Examiner Name	Not Yet Known	
Sheet	2	of	2	Attorney Docket Number	FRAV2003/0005 - US - NP

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		A. LUNDIN et al., Expression and intracellular localization of leptin receptor long isoform-GFP chimera, Biochimica et Biophysica Acta, Vol. 1499, No. 1-2, pp. 130-138	
		B. BAILLEUL et al., The leptin receptor promoter controls expression of a second distinct protein, Nucleic Acids Research, Vol. 25, No. 14, July 15, 1997, pp. 2752-2758	
		K. SERON et al., OB-RGRP and Leprotl1 Define a New Family of Lipid Raft-Associated Tetraspanning Membrane Proteins Localized At the TGN and/or Endosomes, Biology of the Cell, Vol. 93, No. 3/4, Nov. 7, 2001, page 227	
		L. TARTAGLIA et al., Identification and Expression Cloning of a Leptin Receptor, OB-R, Cell, Vol. 83, No. 7, Dec. 29, 1995, pp. 1263-1271	
		N. BOUTE et al., Monitoring the Activation State of the Insulin Receptor Using Bioluminescence Resonance Energy Transfer, Molecular Pharmacology, Vol. 60, No. 4, Oct. 2001, pp. 640-645	
		N. BOUTE et al., The use of resonance energy transfer in high-throughput screening: BRET versus FRET, Trends in Pharmacological Sciences, Vol. 213, No. 8, August 2002, pp. 351-354	
		T. EFFERTH, Leptin contributes to the protection of human leukemic cells from cisplatinum cytotoxicity, Anticancer Research, Vol. 20, No. 4, July 2000, pp. 2541-2546	
		Y. HUANG et al., Cloning and characterization of a novel leptin receptor overlapping transcript-like 1 gene (LEPROTL1), Biochimica et Biophysica Acta, Vol. 1517, No. 2, Jan. 26, 2001, pp. 327-331	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.